Centessa Pharmaceuticals (CNTA) Change in Account Payables (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Change in Account Payables of $3.3 million for Q1 2026, up 255.75% year-over-year from $917212.5 in Q1 2025, and up 348.7% quarter-over-quarter from -$1.3 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) Change in Account Payables (2020 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 7 years of Change in Account Payables data on file, last reported at $3.3 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $3.3 million, up 255.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.4 million (up 322.55% YoY), and the FY2025 annual result was $50000.0, up 101.09% from the prior year.
- Change in Account Payables grew to $3.3 million in Q1 2026 per CNTA's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $3.3 million in Q3 2025 and troughed at -$4.2 million in Q1 2024.
- A 5-year average of $138647.1 and a median of $143000.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables soared 1955.42% in 2024, then slumped 1017.48% in 2025.
- A 5-year view of Change in Account Payables shows it stood at $2.6 million in 2022, then tumbled by 77.43% to $586000.0 in 2023, then slumped by 75.6% to $143000.0 in 2024, then tumbled by 1017.48% to -$1.3 million in 2025, then surged by 348.7% to $3.3 million in 2026.
- Business Quant data shows CNTA's Change in Account Payables at $3.3 million in Q1 2026, -$1.3 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Centessa Pharmaceuticals | 6.15 Bn | 6.15 Bn | - | 3.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.26 Mn |
| Mar 31, 2026 | 3.26 Mn |
| Dec 31, 2025 | -1.31 Mn |
| Dec 31, 2025 | -1.31 Mn |
| Sep 30, 2025 | 3.28 Mn |
| Sep 30, 2025 | 3.28 Mn |
| Jun 30, 2025 | 177,000.00 |
| Jun 30, 2025 | 177,000.00 |
| Mar 31, 2025 | -2.10 Mn |
| Mar 31, 2025 | -2.10 Mn |
| Dec 31, 2024 | 143,000.00 |
| Dec 31, 2024 | 143,000.00 |
| Sep 30, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | -2.18 Mn |
| Jun 30, 2024 | -2.18 Mn |
| Mar 31, 2024 | -4.25 Mn |
| Mar 31, 2024 | -4.25 Mn |
| Dec 31, 2023 | 586,000.00 |
| Dec 31, 2023 | 586,000.00 |